Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 5:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: progestin therapy Clear all
Not listed Phase 2 Interventional

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

NCT02064725
View directory record Official record
Conditions
Recurrent or Persistent Endometrial Carcinoma
Interventions
Sodium cridanimod
Drug
Lead sponsor
Kevelt AS
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 23, 2026, 5:24 PM EDT
Terminated Phase 2 Interventional Results available

An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer

NCT03077698
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Sodium Cridanimod, progestin therapy
Drug
Lead sponsor
Xenetic Biosciences, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
25
States / cities
Burbank, California • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 23, 2026, 5:24 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

NCT02480881
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
BMS-663068, Oral Contraceptive, Loestrin 1.5/30
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 1Phase 2 Interventional

Progesterone Treatment of Blunt Traumatic Brain Injury

NCT00048646
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
IV Progesterone
Drug
Lead sponsor
David Wright
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00451204
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Estriol, Placebo, Copaxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2016 · Synced Sep 23, 2026, 5:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Progestin (Progesterone-Like Hormones) Induced Dysphoria (Depressed Mood, Irritability, Anxiety)

NCT00001770
View directory record Official record
Conditions
Depressive Disorder, Mood Disorder, Psychomotor Agitation
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 23, 2026, 5:24 PM EDT
Recruiting Phase 2 Interventional

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

NCT07436793
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
Interventions
Biopsy Procedure, Curettage Procedure, Hysterectomy, Megestrol Acetate, Progesterone Only Hormone Replacement Therapy
Procedure · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Albuquerque, New Mexico • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 23, 2026, 5:24 PM EDT
Not listed Not applicable Interventional

Stopping Heavy Periods Project

NCT02002260
View directory record Official record
Conditions
Abnormal Uterine Bleeding, Abnormal Uterine Bleeding, Ovulatory Dysfunction, Abnormal Uterine Bleeding, Endometrial Hemostatic Dysfunction
Interventions
Levonorgestrel intrauterine system, Combined oral contraceptives
Device · Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 1, 2021 · Synced Sep 23, 2026, 5:24 PM EDT
Recruiting No phase listed Observational

Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study

NCT05916469
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Bleeding Disorder, Von Willebrand Diseases
Interventions
Levonorgestrel Intrauterine System, Norethindrone Acetate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
10 Years to 24 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 23, 2026, 5:24 PM EDT
Terminated No phase listed Observational

17-OHPC in Pregnancy: IM vs SC Routes

NCT04183452
View directory record Official record
Conditions
Preterm Birth
Interventions
17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-Hydroxyprogesterone Caproate 275 mg SC Dose
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Newark, Delaware • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Sep 23, 2026, 5:24 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Polycystic Ovary Syndrome (PCOS) and Sleep Apnea

NCT00203996
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Obstructive Sleep Apnea
Interventions
continuous positive airway pressure (CPAP), depot leuprolide plus estrogen/progestin replacement, pioglitazone, REM frag, SWS supp
Device · Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 40 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Regulation of Cervical Mucus Secretion

NCT02969590
View directory record Official record
Conditions
Fertility, Contraception
Interventions
Leuprolide acetate, Estrogen and Progesterone Replacement, Progestin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

NCT00229593
View directory record Official record
Conditions
Contraception
Interventions
Nestorone gel, Testosterone Gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Sep 23, 2026, 5:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen and Microvascular Function

NCT06043310
View directory record Official record
Conditions
Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions
Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women

NCT02224313
View directory record Official record
Conditions
Menopause
Interventions
oral estradiol 1.0 mg, oral progesterone 100 mg
Drug
Lead sponsor
Intira Sriprasert
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding

NCT01148420
View directory record Official record
Conditions
Dysfunctional Uterine Bleeding
Interventions
Medroxyprogesterone 17-Acetate, medroxyprogesterone acetate
Drug
Lead sponsor
Women's Health Care Clinic, Torrance, California
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Sep 23, 2026, 5:24 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT

NCT06230770
View directory record Official record
Conditions
Gender, Contraception
Interventions
Bleeding data
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

NCT03317795
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 23, 2026, 5:24 PM EDT
Terminated Phase 3 Interventional

Safety of Estrogens in Lupus: Hormone Replacement Therapy

NCT00000419
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Premarin and Provera
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 2 Interventional Results available

Randomized Trial of Maternal Progesterone Therapy

NCT02133573
View directory record Official record
Conditions
Congenital Heart Disease, Periventricular Leucomalacia, Brain Development, Cardiac Surgery, Neurodevelopmental Disability, Fetal Neuroprotection
Interventions
Progesterone, Vaginal lubricant
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 23, 2026, 5:24 PM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer

NCT07820358
View directory record Official record
Conditions
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
Interventions
Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
Drug · Device · Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 2Phase 3 Interventional

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

NCT03440359
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse
Drug · Diagnostic Test · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Sep 23, 2026, 5:24 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

NCT00310791
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA)
Drug · Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
15 Years to 30 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 23, 2026, 5:24 PM EDT